Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

737
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
737
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

617
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
617
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.9K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethionamide versus ethambutol-containing first-line regimens for TB meningitis.

Antimicrobial agents and chemotherapy·2026
Same author

The Double Burden: Understanding the Impact of Malnutrition on Childhood Cancer Outcomes in Resource-Limited Settings.

International journal of pediatrics·2026
Same author

Diabetes mellitus and its association with tuberculosis clinical presentation and treatment outcomes: results from a prospective cohort study in Ghana.

Frontiers in public health·2026
Same author

Population pharmacokinetics and safety of continuous oxacillin in preterm and term neonates and infants.

Antimicrobial agents and chemotherapy·2026
Same author

Exposure to the Four First-Line Anti-Tuberculosis Drugs and Treatment Outcomes: A Target Trial Emulation Study in Ghana.

Research square·2026
Same author

Pharmacokinetics of Dolutegravir in Children With HIV With and Without Tuberculosis Coinfection Treated According to World Health Organization Dosing Guidelines.

Journal of acquired immune deficiency syndromes (1999)·2026

Related Experiment Video

Updated: Mar 17, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Tuberculosis therapy for 2016 and beyond.

Michael Lauzardo1, Charles A Peloquin2

  • 1a Division of Infectious Diseases and Global Medicine , University of Florida , Gainesville , FL , USA.

Expert Opinion on Pharmacotherapy
|July 27, 2016
PubMed
Summary
This summary is machine-generated.

Tuberculosis treatment faces challenges with drug resistance and persistent organisms. New strategies and drug targets are crucial to shorten therapy and combat this global infectious disease.

Keywords:
Tuberculosisepidemiologyfuturenew drugsnew regimenstherapyvaccine

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Tuberculosis (TB) remains a paramount global infectious disease with significant impact.
  • Progress in TB treatment has lagged compared to other diseases of similar burden.
  • Despite new drug development, their optimal role in TB therapy is yet to be defined.

Purpose of the Study:

  • To review the historical context of current tuberculosis therapy.
  • To examine challenges associated with existing anti-TB medications.
  • To evaluate recently approved and investigational drugs for TB treatment.

Main Methods:

  • Historical review of tuberculosis treatment regimens.
  • Analysis of challenges in current TB drug therapy.
  • Assessment of new and emerging anti-tuberculosis drugs.

Main Results:

  • Current TB therapy faces challenges including drug resistance and the need for prolonged treatment.
  • New drugs offer promise but require strategic integration into treatment protocols.
  • Directly observed therapy and emerging technologies are vital for monitoring and adherence.

Conclusions:

  • Developing new tuberculosis drugs is critical, but preventing further drug resistance is paramount.
  • Strategies to combat drug resistance, especially in resource-limited settings, are essential.
  • Addressing persistent organisms through understanding triggers and identifying new targets may radically shorten TB therapy durations.